Table 3 Univariate and multivariate analyses.

From: Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

Time to disease progression

 

Hazard ratio

CI

p

Univariate predictors

   

AR < 10% Positive (N = 27)

2.28

0.93–5.62

0.073

ER < 10% Positive (N = 27)

4.32

1.46–12.83

0.008

AR and/or ER < 10% Positive (N = 27)

2.35

0.99–5.58

0.052

PR < 10% Positive (N = 27)

0.73

0.32–1.67

0.452

ESR1 mutation (N = 32)

1.47

0.68–3.19

0.329

Ki67 decreaseda (N = 21)

1.79

0.70–4.59

0.225

PTEN and/or PIK3CA (N = 29)

2.02

0.89–4.56

0.092

Multivariate predictors (N = 27)

   

AR < 10% Positive

2.46

0.97–6.22

0.057

ER < 10% Positive

4.69

1.53–14.35

0.007

  1. Select univariate associations with progression are presented. The reference level for “AR and ER < 10% Positive” are participants with AR ≥ 10% positive and/or ER ≥ 10% positive. The reference level for “PTEN and/or PIK3CA” are patients with neither loss. All other univariate associations of interest were non-significant predictors of progression, with p-values greater than 0.2.
  2. aKi67 decreased refers to patients who had a decrease in Ki67 between baseline and week 5. The reference group is patients who had an increase or no change in Ki67 between baseline and week 5.
Back to article page